Abstract:BACKGROUND Tumor recurrence and metastasis lead to a poor prognosis in colorectal cancer (CRC). Necroptosis is closely related to the tumor microenvironment (TME) and affects tumor recurrence and metastasis. We aimed to stratify CRC patients according to necroptosis-related long noncoding RNAs (lncRNAs), which can be used to not only evaluate prognosis and improve precision medicine in clinical practice but also screen potential immunotherapy drugs. AIM To stratify CRC patients according to necroptosis-related lncRNAs (NRLs), which can be used to not only evaluate prognosis and improve precision medicine in clinical practice but also screen potential immunotherapy drugs. METHODS LncRNA expression profiles were collected from The Cancer Genome Atlas. NRLs were identified by coexpression analysis. Cox regression analysis identified a NRL signature. Then, the value of this signature was comprehensively and multidimensionally evaluated, and its reliability for CRC prognosis prediction was assessed with clinical CRC data and compared with that of six other lncRNA signatures. Gene set enrichment analysis, TME analysis and half-maximal inhibitory concentration (IC50) prediction were also performed according to the risk score (RS) of the signature. RESULTS An 8-lncRNA signature significantly associated with overall survival (OS) was constructed, and its reliability was validated with clinical CRC data. Most of the areas under the receiver operating characteristic curves (AUCs) values for 1-, 3- and 5-year OS for this signature were higher than those for the other six lncRNA signatures. OS, disease-specific survival and the progression-free interval were all significantly poorer in the high-risk group. The RS of the signature showed good concordance with the predicted prognosis, with AUCs for 1-, 3- and 5-year OS of 0.79, 0.81 and 0.77, respectively. Additionally, the calibration plots for this signature combined with clinical factors showed that this combination could effectively improve the ability to predict OS. The RS was correlated with tumor stage, lymph node metastasis and distant metastasis. Most of the enriched Kyoto Encyclopedia of Genes and Genomes and Gene Ontology terms were tumor metastasis-related pathways in the high-risk group; these patients showed greater infiltration of immunosuppressive cells, such as cancer-associated fibroblasts, hematopoietic stem cells and M2 macrophages, but less infiltration of infiltrating antitumor effector immune cells, such as cluster of differentiation 8+ T cells and regulatory T cells (Tregs). We explored additional potential immune checkpoint genes and potential immunotherapeutic and chemotherapeutic drugs with relatively low IC50 values. CONCLUSION We identified an NRL signature with strong fidelity that could stably predict prognosis and might be an indicator of the TME of CRC. Furthermore, additional potential immunotherapeutic and chemotherapeutic drugs were explored.

Neat Expression Is Associated With Tumor Recurrence And Unfavorable Prognosis In Colorectal Cancer

Long Non-Coding RNA NEAT1 Overexpression is Associated with Poor Prognosis in Cancer Patients: a Systematic Review and Meta-Analysis

Lncrna NEAT1 Promotes Colorectal Cancer Progression by Increasing Inflammation

Identification of Necroptosis-Related Long Noncoding RNAs for Immunotherapy Selection and Prognosis Prediction in Patients with Colorectal Cancer

The Lncrna NEAT1 Inhibits Mirna-216B and Promotes Colorectal Cancer Progression by Indirectly Activating YY1

Identification of Necroptosis-Related Lncrnas for Prognosis Prediction and Screening of Potential Drugs in Patients with Colorectal Cancer

LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer Via Regulation of Akt Signaling

Genome-wide Analysis of Long Non-Coding RNA Expression and Function in Colorectal Cancer

Aberrant Neat1 Expression is Associated with Clinical Outcome in High Grade Glioma Patients

Nuclear-enriched Abundant Transcript 1 As a Diagnostic and Prognostic Biomarker in Colorectal Cancer

Long Non-Coding RNA NEAT1 Promotes Colorectal Cancer Progression by Competitively Binding Mir-34A with SIRT1 and Enhancing the Wnt/β-catenin Signaling Pathway.

Meta-analysis of the Correlation Between High Expression of lncRNA NEAT1 in Rectal Cancer and Pathological Features and Prognosis

Pan-cancer analysis of long non-coding RNA NEAT1 in various cancers

Upregulation lnc-NEAT1 contributes to colorectal cancer progression through sponging miR-486-5p and activating NR4A1/Wnt/β-catenin pathway

Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness

The Clinical Value of Lncrna NEAT1 in Digestive System Malignancies: A Comprehensive Investigation Based on 57 Microarray and RNA-seq Datasets

Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression

High Expression of Lncrna MALAT1 Suggests a Biomarker of Poor Prognosis in Colorectal Cancer.

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

The lncRNA NEAT1 activates Wnt/β-catenin signaling and promotes colorectal cancer progression via interacting with DDX5

Long Non-Coding RNA NEAT1 Overexpression is Associated with Unfavorable Prognosis in Patients with Hepatocellular Carcinoma after Hepatectomy: A Chinese Population-Based Study